XDx Licenses U. of Minnesota IP to Develop Lupus Dx

Mar 05, 2007

NEW YORK (GenomeWeb News) — XDx will in-license IP from the University of Minnesota that will enable the company to use gene expression technology to assess the status of systemic lupus erythematosus in patients, it said last week.

XDx also said it has entered a separate agreement with UM and the Feinstein Institute for Medical Research in New York that gives the company access to SLE patient samples taken from an NIH-funded study of biomarkers for autoimmune diseases.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Twisting the Results

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Quickly, Quickly

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

'Right to Try' Heads Toward Law

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

This Week in Genome Research

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Featured White Papers

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

Optimized NGS Library Preparation with Acoustic Liquid Handling

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

21

Featured Webinar

Evaluation & Implementation of NGS Liquid Biopsy Assays

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Main menu